<?xml version="1.0" encoding="UTF-8"?>
<p>Polymorphism of CYP2D6 is higher in African Americans and Asians [
 <xref rid="B107-antioxidants-09-00636" ref-type="bibr">107</xref>,
 <xref rid="B108-antioxidants-09-00636" ref-type="bibr">108</xref>,
 <xref rid="B109-antioxidants-09-00636" ref-type="bibr">109</xref>], disproportionately affected by this disease. One study in Lupus patients in Korea showed significant variability in hydroxychloroquine levels due to CYP2D6 polymorphisms [
 <xref rid="B110-antioxidants-09-00636" ref-type="bibr">110</xref>]. Another study in discoid lupus found that 39% had either poor results from fast metabolism or poor outcomes related to toxicity from slow metabolism [
 <xref rid="B111-antioxidants-09-00636" ref-type="bibr">111</xref>]. This accounts for the differences in clinical outcomes with this medication.
</p>
